Coreline Soft Receives Innovation Award for Bio-Medical Technology at Seoul R&D Sharing EventCoreline Soft, a medical AI specialist led by CEO Jinkook Kim, announced that it received an award for its outstanding R&D project results at the "2024 Seoul-type R&D Performance Sharing Event" held at the SETEC Convention and Seminar Hall on the afternoon of December 5. The award recognized the company's achievements in the Bio-Medical Technology Commercialisation Support Project under the Seoul R&D Support Programme.
The Bio-Medical Technology Commercialisation Support Project of the Seoul-type R&D Support Project was designed to promote the commercialization of bio-medical technology and support innovative research by Seoul-based companies. Core Line Soft carried out the project from September 2022 to August 2024 to develop and commercialize innovative technologies for pulmonary embolism and pulmonary hypertension. It was recognized for its achievements as a venture company with outstanding technological and management innovation capabilities, excellent external competitiveness, and high social contribution.
With this support project, Coreline Soft successfully developed an AI-based diagnostic support software for pulmonary embolism and pulmonary hypertension (AVIEW PE) and obtained clinical trial approval and approval from the Ministry of Food and Drug Safety. The software has also been designated as an innovative medical device, recognizing its advanced technology and performance. AVIEW PE will be commercialized and used alongside existing products to build a portfolio for the emergency medicine market.
"This achievement is a good example of how Coreline Soft's technology can create value in the domestic and international medical environment," said Jinkook Kim, CEO of Coreline Soft. He added, "We will continue successfully developing and commercializing technology and strive for sustainable medical innovation.
Coreline Soft is systematically building a range of solutions optimized for the emergency room medical environment. Products for diagnosing cerebral hemorrhage, aortic dissection, and pulmonary embolism have all been designated as innovative medical devices, securing a leading position in the field of emergency medical software. Coreline Soft plans to disseminate these products by maintaining their reimbursement as innovative medical technology for three years, proving their clinical efficacy and eventually formally registering them with health insurance companies. In addition, when the Acute Coronary Syndrome solution, which is currently under development, is released, it will provide comprehensive solutions for the top three thoracic emergencies (aortic dissection, pulmonary embolism and acute coronary syndrome). With this award, Coreline Soft plans to accelerate the research and development of AI-based medical solutions.
